This increase in SMN protein was sustained over 24 months of treatment.76Part 2 is the randomized, double-blind, placebo-controlled portion of the SUNFISH study, which included 180 patients with SMA type 2 or non-ambulatory type 3. The gene discussed is SMN1; the disease is proximal spinal muscular atrophy.